Cargando…
Autoimmune Hemolytic Anemia in Chronic Myeloid Leukemia
BACKGROUND: Autoimmune hemolytic anemia (AIHA) might be associated with underlying hematological malignancies such as chronic lymphocytic leukemia. However, the association between AIHA and chronic myelogenous leukemia is extremely unusual. SUMMARY: We reviewed case reports and series of 54 patients...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845422/ https://www.ncbi.nlm.nih.gov/pubmed/32485715 http://dx.doi.org/10.1159/000507295 |
_version_ | 1783644552675983360 |
---|---|
author | Hamamyh, Tahseen Yassin, Mohamed A. |
author_facet | Hamamyh, Tahseen Yassin, Mohamed A. |
author_sort | Hamamyh, Tahseen |
collection | PubMed |
description | BACKGROUND: Autoimmune hemolytic anemia (AIHA) might be associated with underlying hematological malignancies such as chronic lymphocytic leukemia. However, the association between AIHA and chronic myelogenous leukemia is extremely unusual. SUMMARY: We reviewed case reports and series of 54 patients with chronic myeloid leukemia (CML) who developed autoimmune hemolysis between 1952 and 2018. Almost all the patients were in the chronic phase and were classified into transplant and non-transplant groups. The onset of autoimmune hemolysis was earlier in the transplant group and required second- and third-line therapy to control it. The etiology of hemolysis is poorly understood but attributed in the transplant group to immune reconstitution, viral infections, or CML relapse. On the other hand, it is thought to be related in the non-transplant group to CML medications, especially interferon. KEY MESSAGES: Although AIHA is uncommon in chronic myelogenous leukemia patients, it should be in the differential diagnosis list for those who develop a sudden drop in hemoglobin without a bleeding source. |
format | Online Article Text |
id | pubmed-7845422 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-78454222021-02-01 Autoimmune Hemolytic Anemia in Chronic Myeloid Leukemia Hamamyh, Tahseen Yassin, Mohamed A. Pharmacology Review Article BACKGROUND: Autoimmune hemolytic anemia (AIHA) might be associated with underlying hematological malignancies such as chronic lymphocytic leukemia. However, the association between AIHA and chronic myelogenous leukemia is extremely unusual. SUMMARY: We reviewed case reports and series of 54 patients with chronic myeloid leukemia (CML) who developed autoimmune hemolysis between 1952 and 2018. Almost all the patients were in the chronic phase and were classified into transplant and non-transplant groups. The onset of autoimmune hemolysis was earlier in the transplant group and required second- and third-line therapy to control it. The etiology of hemolysis is poorly understood but attributed in the transplant group to immune reconstitution, viral infections, or CML relapse. On the other hand, it is thought to be related in the non-transplant group to CML medications, especially interferon. KEY MESSAGES: Although AIHA is uncommon in chronic myelogenous leukemia patients, it should be in the differential diagnosis list for those who develop a sudden drop in hemoglobin without a bleeding source. S. Karger AG 2020-11 2020-06-02 /pmc/articles/PMC7845422/ /pubmed/32485715 http://dx.doi.org/10.1159/000507295 Text en Copyright © 2020 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc-nd/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. |
spellingShingle | Review Article Hamamyh, Tahseen Yassin, Mohamed A. Autoimmune Hemolytic Anemia in Chronic Myeloid Leukemia |
title | Autoimmune Hemolytic Anemia in Chronic Myeloid Leukemia |
title_full | Autoimmune Hemolytic Anemia in Chronic Myeloid Leukemia |
title_fullStr | Autoimmune Hemolytic Anemia in Chronic Myeloid Leukemia |
title_full_unstemmed | Autoimmune Hemolytic Anemia in Chronic Myeloid Leukemia |
title_short | Autoimmune Hemolytic Anemia in Chronic Myeloid Leukemia |
title_sort | autoimmune hemolytic anemia in chronic myeloid leukemia |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845422/ https://www.ncbi.nlm.nih.gov/pubmed/32485715 http://dx.doi.org/10.1159/000507295 |
work_keys_str_mv | AT hamamyhtahseen autoimmunehemolyticanemiainchronicmyeloidleukemia AT yassinmohameda autoimmunehemolyticanemiainchronicmyeloidleukemia |